Cancer Gene Therapy (ISSN 1476-5500, 0929-1903) is a journal published by Springer Nature in the United States. It covers Biochemistry, Genetics and Molecular Biology, Molecular Biology and Molecular Medicine. It is indexed in Scopus, Web of Science, MEDLINE, PubMed and HEC. Recorded metrics: impact factor 6.4, Scopus Q1, Web of Science Q1, CiteScore 11.1 and HEC W-Category. Article processing charge: USD 5,190. This profile brings together the journal's ISSN, publisher, country, subject area, HEC category, Scopus data, SJR and SCImago rank, Web of Science data, impact factor, indexing, open access status, APC, aims and scope, about the journal, author instructions, journal website and registration details from the most reputable indexes, in one place.
Cancer Gene Therapy
Record last updated . Check current status at HEC HJRS, Scopus and the Web of Science Master Journal List before submitting. About our data.
Journal lists: Q1 journals · HEC W category journals · Scopus journals · Web of Science journals · MEDLINE journals · PubMed journals · SCImago journals · SCIE journals · Impact factor journals · Scopus Q1 journals · Web of Science Q1 journals · Q1 Biochemistry journals · Q1 Genetics and Molecular Biology journals
Quick answers about Cancer Gene Therapy
Is Cancer Gene Therapy HEC recognised?
Yes. The catalogue records Cancer Gene Therapy in HEC category W of the HEC Journal Recognition System, where W is the highest and Y the lowest category. Confirm the current category on HEC's HJRS website before you submit.
Is Cancer Gene Therapy indexed in Scopus?
Yes. Cancer Gene Therapy is listed as Scopus-indexed, in quartile Q1, with a CiteScore of 11.1. Check its current status on the Scopus Sources page.
Is Cancer Gene Therapy in Web of Science?
Yes. Cancer Gene Therapy is listed as a Web of Science journal in the Science Citation Index Expanded (SCIE), with Web of Science quartile Q1. Confirm on Clarivate's Master Journal List.
What is the impact factor of Cancer Gene Therapy?
The recorded journal impact factor of Cancer Gene Therapy is 6.4. Clarivate updates impact factors every year in Journal Citation Reports.
Is Cancer Gene Therapy open access, and what does it charge?
Cancer Gene Therapy is not recorded as fully open access and its APC is USD 5,190. Fees change, so check the journal's website before you submit.
Who publishes Cancer Gene Therapy?
Cancer Gene Therapy is published by Springer Nature in United States, under ISSN 1476-5500 and 0929-1903.
Research profile
- 2,984articles indexed
- 99,604citations
- 116h-index
- 6.792-year mean citedness
- 1992first year indexed
Main research topics: Virus-based gene therapy research, Immunotherapy and Immune Responses, RNA Interference and Gene Delivery, Bacterial Cancer Therapy, Cancer-related Molecular Pathways, Cancer-related molecular mechanisms research.
Source: OpenAlex (CC0), retrieved 21 November 2026. Counts cover works OpenAlex has indexed and differ from Scopus and Web of Science.
Browse similar journals
- Biochemistry journals (2,272)
- Genetics and Molecular Biology journals (2,274)
- Molecular Biology journals (429)
- Journals indexed in Scopus (31,185)
- Journals indexed in Web of Science (22,643)
- Journals indexed in MEDLINE (3,645)
- Journals indexed in PubMed (16,086)
- Journals indexed in HEC (34,823)
- Scopus Q1 journals (9,924)
- Web of Science Q1 journals (4,519)
- HEC W-Category journals (13,616)
- Journals published in the United States (7,575)
- Springer Nature journals (2,655)